(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/buy_a_domain.png

Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more

www.crwedomains.com

ad2

http://crweworld.com/assets/images/ad/ad4.png

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com

ad5

http://crweworld.com/assets/images/ad/Pathology_Laboratories.png

Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.

www.QuestDiagnostics.com






844 Result: Intel

Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

August 29th, 2016

Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

August 22nd, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more

Xplore Receives $13.5M Follow-On Order from Top Telecommunications Service Provider for Android(TM)-Powered Fully Rugged Tablet PCs

August 16th, 2016

Longtime customer to transition second division to rugged tablet-only mobility solution; Chooses XSLATE D10 platform to power fiber optic service workflows AUSTIN, Texas / CRWE PRESS RELEASE / August 16, 2016 - Xplore Technologies Corp. (NASDAQ: X. Read more

ViewRay's MRIdian System Receives Japanese Regulatory Approval (Shonin)

August 15th, 2016

Expands MRI-Guided Radiation Therapy Access to World’s Third Largest Market CLEVELAND / CRWE PRESS RELEASE / August 15, 2016 – ViewRay, Inc. (Nasdaq: VRAY)announced today that the company received Shonin approval from the Japanese. Read more

Pluristem's Phase III Critical Limb Ischemia Study Wins $8 Million Grant from Europe's Horizon 2020 Program

August 09th, 2016

- The study will enroll about 250 patients in Europe and the U.S. - The grant will cover a significant portion of the study expenses - PLX-PAD was previously selected by the EMA to be developed via the Adaptive Pathways project HAIFA, ISRAE. Read more

Pluristem Receives Positive Feedback from FDA and Gears Up for Phase III Trial of PLX-PAD in Critical Limb Ischemia

August 02nd, 2016

- CLI is a severe unmet medical need whose treatment addresses a $12 billion global market - Multinational study to be conducted in U.S. and Europe - Estimated trial enrollment of approximately 250 patients - Primary endpoint for BLA will be time . Read more

Silicom Penetrates Tier-1 Lawful Interception Company: Achieves Multi-Million Dollar Design Win for 100G Intelligent Bypass Switches

August 01st, 2016

- $1.6M in POs For Delivery in Q3 Received So Far – KFAR SAVA, Israel / CRWE PRESS RELEASE / August 1, 2016 - Silicom Ltd. (NASDAQ: SILC) today announced that it has achieved a major Design Win from a top-tier Lawful Interception company. Read more

Shire Recommends ADS Holders Reject TRC Capital's "Mini-Tender Offer"

July 29th, 2016

Dublin, Ireland / CRWE PRESS RELEASE / July 29, 2016 – Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited “mini-tender” offer made by TRC Capital Corporation (“TRC Capital”) to purchase up to 1,000,0. Read more

ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy

July 25th, 2016

The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more

Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III Trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET Trial)

July 21st, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / July 21, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced updated results from the Phase III clinical trial of Puma's investigational drug PB272 (neratinib) for t. Read more

Ballard Signs Follow-On Technology Solutions Agreement With Leading Global Automotive OEM

July 20th, 2016

VANCOUVER, CANADA / CRWE PRESS RELEASE / July 20, 2016 – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced that it has signed a follow-on Technology Solutions contract with an unnamed leading global automotive OEM. Under the c. Read more

Transgenomic Licenses Commercial Rights to Its Long QT Syndrome DNA Testing Portfolio to LabCorp

July 20th, 2016

LabCorp’s DNA Testing for Long QT Syndrome, a Congenital Heart Rhythm Disorder Associated with Potentially Lethal Arrhythmias, is Enhanced by TBIO’s Intellectual Property OMAHA, NE / CRWE PRESS RELEASE / July 20, 2016 - Transgenom. Read more

Chronos Therapeutics Acquires Pre-clinical Programmes From Shire

July 20th, 2016

Expands Pipeline With Novel CNS Assets in a Transformative Deal Oxford, UK / CRWE PRESS RELEASE / July 20, 2016 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, today. Read more

Ballard Inks Landmark Deal For Local Production of Fuel Cell Stacks in China, With $168M Estimated Value Over 5-Years

July 18th, 2016

VANCOUVER, CANADA and FOSHAN, CHINA / CRWE PRESS RELEASE / July 18, 2016 – Ballard Power Systems (NASDAQ: BLDP; TSX: BLD) today announced the signing of definitive agreements in Foshan, China with Guangdong Nation Synergy Hydrogen Power Technol. Read more

Embraer and Boeing to Collaborate on Worldwide Sales, Support of KC-390 Medium Airlift

July 11th, 2016

FARNBOROUGH, UNITED KINGDOM / CRWE PRESS RELEASE / July 11, 2016 – Embraer [NYSE: ERJ; BOVESPA: EMBR3] and Boeing [NYSE: BA] have signed a teaming agreement to jointly market and support the KC-390, a multi-mission mobility and aerial refueling. Read more

Load More Content